alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Election Assistance Commission

# AGENCY:

United States Election Assistance Commission.

# ACTION:

Notice of Public Meeting. 

# DATE AND Time:

Thursday, February 7, 2008 10 a.m.-1 p.m.

# Place:

Hyatt Regency on Capitol Hill, 400 New Jersey Avenue, NW., Washington, DC 20001. (Metro Stop: Union Station).

# Agenda:

                    Commissioners will receive an update on HAVA Funding Issues. Commissioners will consider and vote on the following studies: Study on Feasibility of Free Absentee Voting Postage; Study on use of Social Security Information of First Time Voters Who Register to Vote by Mail. Commissioners will consider and vote on an Interim                           ( print page 5528)                        Policy for Changes to State Specific Instructions on National Mail Voter Registration Form. Commissioners will consider and vote on a Disclaimer proposal to State Instructions Portion of the NVRA Form. The Commission will consider other administrative matters.                

This meeting will be open to the public.

# Person To Contact For Information:

Bryan Whitener, Telephone: (202) 566-3100.

Thomas R. Wilkey, 

Executive Director, U.S. Election Assistance Commission.

[FR Doc. 08-423 Filed 1-25-08; 4:13 pm]

BILLING CODE 6820-KF-M
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
  AMENDED, AND IS TRANSFERABLE ONLY UPON THE CONDITIONS SPECIFIED IN THE
  NOTE AGREEMENT REFERRED TO HEREIN.

              Promissory Note Due February 29, 2004

                                                                 $20,000.00

      GK INTELLIGENT SYSTEMS, INC, a Delaware public corporation, (herein
called the "Maker") for value received, hereby promises to pay to JOEL PICKELL
or his registered assigns ("Holder"), the principal sum of twenty thousand
dollars ($20,000.00) and annualized interest of 0 %.  Payment of the principal
and interest of this Note will be made by check on February 29, 2004 (unless
extended) at the offices of the Maker maintained in Houston, Texas, or mailed
to the address of the person entitled thereto as such address shall be
provided to the Maker, in such coin or currency of the United States of
America.

      This Note shall be collateralized by three hundred thirty three thousand
three hundred thirty three  (333,333) shares of common stock in GK Intelligent
Systems, Inc. currently registered in the name of "GK Intelligent Systems".
Holder may, at its option, accept payment of all or part of the principal
portion of this Note in the form of the heretofore described common stock on a
pro rata basis using a price per share of six cents.  Holder may make this
election on or before the due date of February 29, 2004.

      No provision of this Note shall alter or impair the obligation of the
Maker, which is absolute and unconditional, to pay the principal of this Note
at the times, places and rate, and in the coin or currency, herein prescribed.

      The Note may be transferred upon surrender of this Note or registration
of transfer at the offices or agencies of the Maker in Houston, Texas duly
endorsed by, or accompanied by a written instrument of transfer in
substantially the form accompanying this Note duly executed by, the holder
hereof or his attorney duly authorized in writing, and thereupon one or more
new Notes, of authorized denominations and for the same aggregate principal
amount, will be issued to the designated transferee or transferees.

      Prior to due presentment of this Note for registration of transfer, the
Maker, and any agent of the Maker may treat the person in whose name this Note
is registered as the owner hereof for all purposes, whether or not this Note
be overdue, and neither the Maker nor any such agent shall be affected by
notice to the contrary.

      This Note represents the final agreement between the parties and may not
be contradicted by evidence of prior, contemporaneous, or subsequent oral
agreements of the parties.  There are no unwritten oral agreements between the
parties.

      IN WITNESS WHEREOF, GARY KIMMONS, CEO of GK Intelligent Systems, Inc.
has caused this instrument to be executed.

Dated:  December 31, 2003.

                                   /s/ Gary F. Kimmons
                                  _________________________________________
                                  GARY KIMMONS, CEO, GK INTELLIGENT SYSTEMS
EXHIBIT 31.02



Certification of Robert M. Kline, Chief Financial Officer, pursuant to

Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended



I, Robert M. Kline, certify that:



1. I have reviewed this quarterly report on Form 10-Q of Gold Star Tutoring Services, INC. for the quarterly period ended September 30, 2008;



2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;



(b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and



5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



October 29, 2008

/s/Robert M. Kline__________________

Robert M. Kline, Treasurer

Chief Financial Officer

Principal Accounting and Financial Officer
NOTE: This order is nonprecedential. 

 

United States Court of Appeals 

for the Federal Circuit ______________________

In Re ENTRESTO (SACUBITRIL/VALSARTAN)

-------------------------------------------------

NOVARTIS PHARMACEUTICALS CORPORATION,

Plaintiff-Appellant

v.

TORRENT PHARMA INC., TORRENT 

PHARMACEUTICALS LTD.

Defendants-Appellees

-------------------------------------------------

NOVARTIS PHARMACEUTICALS CORPORATION,

Plaintiff-Appellant

v.

ALEMBIC PHARMACEUTICALS LIMITED, 

ALEMBIC PHARMACEUTICALS INC.,

Defendants

-------------------------------------------------

NOVARTIS PHARMACEUTICALS CORPORATION,

Plaintiff-Appellant

v.

Case: 23-2218 Document: 53 Page: 1 Filed: 03/06/2024
2 IN RE ENTRESTO (SACUBITRIL/VALSARTAN)

HETERO USA, INC., HETERO LABS LIMITED, 

HETERO LABS LIMITED UNIT-III, MSN 

PHARMACEUTICALS, INC., MSN LABORATORIES 

PRIVATE LTD., MSN LIFE SCIENCES PRIVATE 

LTD.,

Defendants-Appellees

______________________

2023-2218, 2023-2219, 2023-2220, 2023-2221

______________________

Appeals from the United States District Court for the 

District of Delaware in Nos. 1:19-cv-01979-RGA, 1:19-cv02021-RGA, 1:19-cv-02053-RGA, and 1:20-md-02930-RGA, 

Judge Richard G. Andrews.

-------------------------------------------------

NOVARTIS PHARMACEUTICALS CORPORATION,

Plaintiff-Appellant

v.

MYLAN PHARMACEUTICALS INC.,

Defendant-Appellee

______________________

2023-2260

______________________

Appeal from the United States District Court for the 

Northern District of West Virginia in No. 1:19-cv-00201-

TSK, Chief Judge Thomas S. Kleeh.

______________________

O R D E R

Novartis Pharmaceuticals Corporation and Mylan 

Pharmaceuticals Inc. submit a joint stipulation to dismiss

Case: 23-2218 Document: 53 Page: 2 Filed: 03/06/2024
IN RE ENTRESTO (SACUBITRIL/VALSARTAN) 3

Appeal No. 2023-2260 pursuant to Rule 42(b)(1) of the Federal Rules of Appellate Procedure, agreeing that each bear 

its own costs with respect to Appeal No. 2023-2260. 

Upon consideration thereof,

 IT IS ORDERED THAT: 

(1) Appeal No. 2023-2260 is deconsolidated from Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-

2221, and Appeal No. 2023-2260 is dismissed. Each side 

shall bear its own costs regarding Appeal No. 2023-2260. 

(2) The stay in Appeal Nos. 2023-2218, 2023-2219, 

2023-2220, and 2023-2221 is lifted. 

 (3) The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 

2023-2219, 2023-2220, and 2023-2221. 

March 6, 2024

 Date

FOR THE COURT

ISSUED AS A MANDATE (as to Appeal No. 2023-2260 

only): March 6, 2024 

Case: 23-2218 Document: 53 Page: 3 Filed: 03/06/2024
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350

The undersigned, Bernard Perez, the Chief Executive Officer and Chief Financial Officer of Tidewater Resources Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the report on Form 10-QSB of Tidewater Resources Inc. for the quarterly period ended March 31, 2008, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the report on Form 10-QSB fairly presents in all material respects the financial condition and results of operations of Tidewater Resources Inc.

Date:     June 9, 2008.

| | "Bernard Perez"                                                                                               
| | --------------------------------------------------------------------------------------------------------------
| | Bernard Perez
President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and a director

__________
# National Crime Victims' Rights Week, 2008

During National Crime Victims' Rights Week we highlight our dedication to protecting and strengthening the rights of crime victims and their families. 

My Administration is committed to providing services and resources for victims of crime so that they can find justice, hope, and healing in their lives. To assist victims of domestic violence and their children, my Family Justice Center Initiative established comprehensive support centers in communities across the country. Through the Justice for All Act of 2004, we expanded DNA testing and enhanced the scope and enforceability of crime victims' rights. In 2006, I signed into law the Adam Walsh Child Protection and Safety Act to expand the National Sex Offender Registry, increase Federal penalties for crimes against children, and protect our children while on the Internet. I also support a Crime Victims' Rights Amendment to the Constitution. Through these and other efforts, we can better protect our citizens and our communities. 

During National Crime Victims' Rights Week, we recognize the advocates, counselors, and others who assist victims in their time of need, and the law enforcement personnel who work to bring offenders to justice. To learn more about victims' rights, Americans can visit www.crimevictims.gov. By working together, we can help protect crime victims and build a society that respects the life and value of every person. 

                        NOW, THEREFORE, I, GEORGE W. BUSH, President of the United States of America, by virtue of the authority vested in me by the Constitution and laws of the United States, do hereby proclaim April 13 through April 19, 2008, as National Crime Victims' Rights Week. I encourage all Americans to promote awareness of victims' rights and advance this important cause.                               ( print page 20522)    

IN WITNESS WHEREOF, I have hereunto set my hand this eleventh day of April, in the year of our Lord two thousand eight, and of the Independence of the United States of America the two hundred and thirty-second. 

[FR Doc. 08-1137

Billing code 3195-01-P
<TABLE> <S> <C>

<ARTICLE>                                                             5
<MULTIPLIER>                                                      1,000
       
<S>                                                                 <C>
<PERIOD-TYPE>                                                      YEAR
<FISCAL-YEAR-END>                                           JUL-31-1998
<PERIOD-END>                                                JUL-31-1998
<CASH>                                                            7,816
<SECURITIES>                                                      1,501
<RECEIVABLES>                                                    27,446
<ALLOWANCES>                                                      1,150
<INVENTORY>                                                       9,167
<CURRENT-ASSETS>                                                 45,552
<PP&E>                                                            9,326
<DEPRECIATION>                                                    3,351
<TOTAL-ASSETS>                                                   56,894
<CURRENT-LIABILITIES>                                            19,440
<BONDS>                                                               0
<PREFERRED-MANDATORY>                                                 0
<PREFERRED>                                                           0
<COMMON>                                                             81
<OTHER-SE>                                                       37,264
<TOTAL-LIABILITY-AND-EQUITY>                                     56,894
<SALES>                                                         202,530
<TOTAL-REVENUES>                                                202,530
<CGS>                                                           171,930
<TOTAL-COSTS>                                                   171,930
<OTHER-EXPENSES>                                                 27,414
<LOSS-PROVISION>                                                      0
<INTEREST-EXPENSE>                                                   41
<INCOME-PRETAX>                                                   3,732
<INCOME-TAX>                                                      1,560
<INCOME-CONTINUING>                                               2,172
<DISCONTINUED>                                                        0
<EXTRAORDINARY>                                                       0
<CHANGES>                                                             0
<NET-INCOME>                                                      2,172
<EPS-PRIMARY>                                                       .26
<EPS-DILUTED>                                                       .26
        

</TABLE>
[Federal Register Volume 72, Number 242 (Tuesday, December 18, 2007)]
[Notices]
[Pages 71725-71726]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-6097]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]


In the Matter of: Xiiva Holdings Inc.; Order of Suspension of 
Trading

December 14, 2007.
    It appears to the Securities and Exchange Commission that the 
market for the securities of Xiiva Holdings, Inc. (``Xiiva,'' trading 
symbol XIVAF), may be reacting to manipulative forces or deceptive 
practices and that there is insufficient current public information 
about the issuer upon which an informed investment decision may be 
made, particularly concerning (1) the identity of and prior securities 
fraud judgments against persons who appear to be involved in the offer 
and sale of

[[Page 71726]]

Xiiva shares; (2) the financial performance and business prospects of 
Xiiva; and (3) offerings to foreign investors and any restrictions on 
the resale of shares.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed company.
    Therefore, it is ordered, pursuant to section 12(k) of the 
Securities Exchange Act of 1934, that trading in the above-listed 
company is suspended for the period of 9:30 a.m. EST, December 14, 2007 
through 11:59 p.m. EST, on December 28, 2007.

    By the Commission.
J. Lynn Taylor,
Assistant Secretary.
[FR Doc. 07-6097 Filed 12-14-07; 12:26 pm]
BILLING CODE 8011-01-P
January 24, 2006

Mr. Larry Elliott, Director
Office of Compensation Analysis and Support
National Institute for Occupational
Health and Safety
4676 Columbia Parkway, C-46
Cincinnati, OH 45226

RE:
US DOL file number

Dear Mr. Elliott:

I was pleased to see that NIOSH is accepting public comment regarding proposed
changes to benefit claims made by Hanford workers with lymphoma.

My mother, ., worked at Hanford for more than 26 years. During her
employment on the nuclear reservation, she was snosed with d cancer, which
resulted in surgery in _ She filed a claim for benefits under the dose reconstruction
project/EEOICPA.

The result of the DOL analysis of my mother’s case determined that the probability of
causation of the primary cancer *) was 42.67%, just 7.33% difference from the
50% level established.

To be honest, I feel the 50% target is unreasonable and illogical. The facts are that my
mother worked at Hanford, she was exposed to radiation during her employment, and she
contracted cancer which is a known result from such exposure. Setting an
arbitrarily high-percentage for probability of cause doesn’t make sense.

I appreciate NIOSH reconsidering its previous probability target, and allowing
recalculation for Hanford employees, such as

Sincerely,
[Federal Register Volume 73, Number 18 (Monday, January 28, 2008)]
[Notices]
[Page 4882]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-307]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Dental & Craniofacial Research; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Dental and Craniofacial 
Research Special Emphasis Panel, Review R25.
    Date: February 7, 2008.
    Time: 2 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Bethesda, MD 20892. (Telephone Conference Call)
    Contact Person: Sooyoun (Sonia) Kim, MS, Scientific Review 
Officer, Scientific Review Branch, Division of Extramural 
Activities, NIDCR/NIH, 6701 Democracy Blvd., Rm 675, Bethesda, MD 
20892-4878, (301) 594-4827, <a href="/cdn-cgi/l/email-protection#95fefcf8e6d5f0f8f4fcf9bbfbfcf1e7bbfbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="e18a888c92a1848c80888dcf8f888593cf8f8889cf868e97">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute of Dental and Craniofacial 
Research Special Emphasis Panel, Review R13s.
    Date: February 29, 2008.
    Time: 9 p.m. to 11 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892. (Virtual meeting)
    Contact Person: Sooyoun (Sonia) Kim, MS, Scientific Review 
Officer, Scientific Review Branch, Division of Extramural 
Activities, NIDCR/NIH, 6701 Democracy Blvd., Rm. 675, Bethesda, MD 
20892-4827, <a href="/cdn-cgi/l/email-protection#660d0f0b1526030b070f0a48080f021448080f0e48010910"><span class="__cf_email__" data-cfemail="f3989a9e80b3969e929a9fdd9d9a9781dd9d9a9bdd949c85">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral 
Diseases and Disorders Research, National Institutes of Health, HHS)

    January 17, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-307 Filed 1-25-08: 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>